Publication
Clinical performance of an infliximab rapid quantification assay
dc.contributor.author | Magro, F. | |
dc.contributor.author | Afonso, J. | |
dc.contributor.author | Lopes, S. | |
dc.contributor.author | Coelho, R. | |
dc.contributor.author | Gonçalves, R. | |
dc.contributor.author | Caldeira, P. | |
dc.contributor.author | Lago, P. | |
dc.contributor.author | Sousa, H. | |
dc.contributor.author | Ramos, J. | |
dc.contributor.author | Gonçalves, A. | |
dc.contributor.author | Ministro, P. | |
dc.contributor.author | Rosa, I. | |
dc.contributor.author | Meira, T. | |
dc.contributor.author | Andrade, P. | |
dc.contributor.author | Soares, J. | |
dc.contributor.author | Carvalho, D. | |
dc.contributor.author | Sousa, P. | |
dc.contributor.author | Vieira, A. | |
dc.contributor.author | Lopes, J. | |
dc.contributor.author | Dias, C. | |
dc.contributor.author | Geboes, K. | |
dc.contributor.author | Carneiro, F. | |
dc.date.accessioned | 2018-10-25T14:40:48Z | |
dc.date.available | 2018-10-25T14:40:48Z | |
dc.date.issued | 2017-09 | |
dc.description.abstract | BACKGROUND: Therapeutic drug monitoring (TDM)-based algorithms can be used to guide infliximab (IFX) adjustments in inflammatory bowel disease (IBD) patients. This study aimed to explore a rapid IFX-quantification test from a clinical perspective. METHODS: This manuscript describes a prospective cohort study involving 110 ulcerative colitis (UC) patients on the maintenance phase of IFX. IFX trough levels were quantified using a rapid quantification assay and a commonly-used reference kit. RESULTS: Irrespective of the assay used to measure IFX, its through levels were statistically different between patients with and without endoscopic remission (Mayo endoscopic score = 0), as well as between patients stratified by their faecal calprotectin (FC) levels. Despite the fact that the two methods correlated well with each other [Spearman's rank correlation coefficient = 0.843, p < 0.001; intraclass correlation coefficients = 0.857, 95% confidence interval (CI): 0.791-0.903], there was a discernible systematic variation; values obtained with the reference kit were on average 2.62 units higher than those obtained with the rapid assay. Notwithstanding, 3 µg/ml was shown to be an acceptable cut-off to assess endoscopic status and inflammatory burden levels using both assays. The percentage of patients that had a positive outcome when the IFX concentration measured by the rapid assay ranked above 3 µg/ml was 88% both for a Mayo endoscopic score ⩽ 1 and for an FC concentration <250 µg/g. CONCLUSIONS: Based on this study, we concluded that using the rapid IFX assessment system with a 3 µg/ml threshold is a reliable alternative to the time-consuming enzyme-linked immunosorbent assays in patients on the maintenance phase of IFX. | pt_PT |
dc.description.sponsorship | This work was supported by the Portuguese IBD Group (GEDII, Grupo de Estudo da Doença Inflamatória Intestinal) | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Therap Adv Gastroenterol. 2017 Sep;10(9):651-660 | pt_PT |
dc.identifier.doi | 10.1177/1756283X17722916 | pt_PT |
dc.identifier.issn | 1756-283X | |
dc.identifier.issn | 1756-2848 | |
dc.identifier.uri | http://hdl.handle.net/10400.16/2235 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | SAGE Publications | pt_PT |
dc.relation.publisherversion | http://journals.sagepub.com/doi/abs/10.1177/1756283X17722916?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& | pt_PT |
dc.subject | infliximab | pt_PT |
dc.subject | therapeutic window | pt_PT |
dc.subject | ulcerative colitis | pt_PT |
dc.title | Clinical performance of an infliximab rapid quantification assay | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.conferencePlace | England | pt_PT |
oaire.citation.endPage | 660 | pt_PT |
oaire.citation.issue | 9 | pt_PT |
oaire.citation.startPage | 651 | pt_PT |
oaire.citation.title | Therapeutic Advances in Gastroenterology | pt_PT |
oaire.citation.volume | 10 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |